Publications

Publications

(Click titles for link to publishers website; ⊥ = equal contribution; * = corresponding authors)

36. Lipid-Modulated, Graduated Inhibition of N-Glycosylation Pathway Priming Suggests Wide Tolerance of ER Proteostasis to Stress

A. M. Giltrap, N. Morris, Y. Y. Dong, S. A. Cochrane, T. Krulle, S. Hoekman, M. Semmelroth, C. Wollnik, E. P. Carpenter, Y. Rudhard, J. Hollick, A. Parkes, B. G. Davis*

ACS Cent. Sci. 2024, under revision

 

35. A Novel Approach for the Synthesis of the Cyclic Lipopeptide Globomycin

S. J. Bann, S. A. Cochrane*

RSC Med. Chem. 2024, accepted

 

34. Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii

P. J. Alexander, L. B. Oyama, H. Olleik, F. Godoy Santos, S. O’Brien, A. Cookson, S. A. Cochrane, B. F. Gilmore, M. Maresca, S. A. Huws*

NPJ Biofilms Microbiomes 2024, 10, 92

 

33. A classic antibiotic reimagined: Rationally designed bacitracin variants exhibit potent activity against vancomycin-resistant pathogens

N. P. Buijs, H. C. Vlaming, I. Kotsogianni, M. Arts, J. J. Willemse, Y. Duan, F. M. Alexander, S. A. Cochrane, Tanja Schneider, Nathaniel I. Martin*

Proc. Natl. Acad. Sci. USA 2024, 121, e2315310121

 

32. Discovery and derivatization of tridecaptin antibiotics with altered host specificity and enhanced bioactivity

N. V. Machushynets, K. Al Ayed, B. Terlouw, C. Du, N. Buijs, J. Willemse, S. S. Elsayed, J. Schill, V. Trebosc, M. Pieren, F. M. Alexander, S. A. Cochrane, M. R. Liles, M. H. Medema, N. I. Martin, G. P. van Wezel

ACS Chem. Biol. 2024, 19, 1106-1115

 

31. De novo design of cyclic peptide inhibitors of a bacterial membrane lipoprotein peptidases

T. W. Craven⊥, M. D. Nolan⊥, J. Bailey⊥,S. Olatunji, S. J. Bann, K. Bowen, N. Ostrovitsa, T. M. Da Costa, R. D. Ballantine, D. Weichert, P. M. Levine, L. J. Stewart, G. Bhardwaj, J. A. Geoghegan,* S. A. Cochrane,* E. M. Scanlan,* M. Caffrey,* D. Baker*

ACS Chem. Biol. 2024, 19, 1125-1130

30. Plectasin kills bacteria by a Ca2+-sensitive supramolecular mechanism

S. Jekhmane, M. G. N. Derks, S. Maity, C. J. Slingerland, K. H. M. E. Tehrani, J. Medeiros-Silva, V. J. Charitou,  D. Ammerlaan, C. Fetz, N. A. Consoli, R. V. K. Cochrane, E. J. Matheson, M. van der Weijde, B. O. W. Elenbaas, F. Lavore, R. Cox, J. H. F. F. Lorent, M. Baldus, M. Kunzler, M. Lelli, S. A. Cochrane, N. I. Martin, W. H. Roos, E. Breukink*, M. Weingarth* 

Nat. Microbiol. 2024, 9, 1778–1791

 

29. Optimizations of Lipid II Synthesis: An Essential Glycolipid Precursor in Bacterial Cell Wall Synthesis and a Validated Antibiotic Target

M. Karak, C. R. Cloonan, B. R. Baker, R. V. K. Cochrane, S. A. Cochrane*

Beilstein J. Org. Chem. 2024, 20, 220-227

 

28. Targeting membrane-bound bacterial cell wall precursors: A tried and true antibiotic strategy in nature and the clinic

N. P. Buijse⊥, E. J. Matheson⊥, S. A. Cochrane* and N. I. Martin*

Chem. Commun. 2023, 59, 7685-7703.

 

27. Linearization of the Brevicidine and Laterocidine Lipopeptides Yields Analogues that Retain Full Antibacterial Activity

R. D. Ballantine⊥, K. Al Ayed⊥, S. J. Bann, M. Hoekstra, N. I. Martin* and S. A. Cochrane*

J. Med. Chem. 2023, 66, 6002-6009.

 

26. Synthesis and Structure-Activity Relationship Studies of N-Terminal Analogues of the Lipopeptide Antibiotics Brevicidine and Laterocidine

R. D. Ballantine⊥, K. Al Ayed⊥, S. J. Bann, M. Hoekstra, N. I. Martin* and S. A. Cochrane*

RSC Med. Chem. 2022, 13, 1640-1643.

 

25. Synthetic Studies with the Brevicidine and Laterocidine Lipopeptide Antibiotics Including Analogues with Enhanced Properties and in vivo Efficacy

K. Al Ayed⊥, R. D. Ballantine⊥, M. Hoekstra, S. J. Bann, C. M. J. Wesseling, A. T. Bakker, Z. Zhong, Y-X Li, N. C. Brüchle, M. van der Stelt, S. A. Cochrane* and N. I. Martin*

Chem. Sci. 2022, 13, 3563.

 

24. Binding Studies Reveal Phospholipid Specificity and its Role in the Calcium-Dependent Mechanism of Action of Daptomycin

I. Kotsogianni, T. M. Wood, F. M. Alexander, S. A. Cochrane and N. I. Martin*

ACS Infectious Diseases, 2021, 7, 2612.

 

 

23. The Tridecaptins: Non-Ribosomal Peptides That Selectively Target Gram-Negative Bacteria

S. J. Bann, R. D. Ballantine and S. A. Cochrane*

RSC Med. Chem. 2021, 12, 538.

 

22. Undecaprenol Kinase: Function, Mechanism and Substrate Specificity of a Potential Antibiotic Target

B. R. Baker, C. M. Ives, A. Bray, M. Caffrey* and S. A. Cochrane*

Eur. J. Med. Chem. 2021, 210, 113062.

 

21. From Plant to Probe: Semi-Synthesis of Labelled Undecaprenol Analogues Allows Rapid Access to Probes for Antibiotic Targets

R. V. K. Cochrane, F. M. Alexander, C. Boland, S. K. Fetics, M. Caffrey and S. A. Cochrane*

Chem. Commun., 2020, 56, 8603.

 

20. Breaking Down the Cell Wall: Strategies for Antibiotic Discovery Targeting Bacterial Transpeptidases

S. A. Cochrane and C. T. Lohans*

Eur. J. Med. Chem. 2020, 194, 113062.

 

19. Observation of the Unbiased Conformers of Putative DNA-Scaffold Ribosugars

C. Calabrese, I. Uriarte, A. Insausti, M. Vallejo-López, F. J. Basterretxea, S. A. Cochrane, B. G. Davis*, F. Corzana*, and E. J. Cocinero*

ACS Cent. Sci. 2020, 6, 293.

 

18. A Chemical-Intervention Strategy to Circumvent Peptide Hydrolysis by D-Stereoselective Peptidases

S. J. Bann, R. D. Ballantine, Y-X. Li, P-Y. Qian and S. A. Cochrane*

J. Med. Chem. 2019, 62, 10466.

 

17. Dissecting the Binding Interactions of Teixobactin with the Bacterial Cell Wall Precursor Lipid II

S. Chiorean, I. Antwi, D. W. Carney, I. Kotsogianni, A. M. Giltrap, F. M. Alexander, S. A. Cochrane, R. J. Payne, N. I. Martin, A. Henninot and J. C. Vederas*

ChemBioChem 2019, 21, 781.

 

16. Tridecaptin-Inspired Antimicrobial Peptides with Activity Against Multidrug-Resistant Gram-Negative Bacteria

R. D. Ballantine, C. E. McCallion, E. Nassour, S. Tokajian and S. A. Cochrane*

Med. Chem. Commun. 2019, 10, 484.

 

15. Rational Design of New Cyclic Analogues of the Antimicrobial Lipopeptide Tridecaptin A1

R. D. Ballantine,  Y-X. Li,  P-Y. Qian  and S. A. Cochrane*

Chem. Commun. 2018, 54, 10634.

 

 

14. Insights into the Mechanism of Action of the Two-Peptide Lantibiotic Lacticin 3147

A. Bakhtiary, S. A. Cochrane, P. Mercier, R. T. McKay, M. Miskolzie, C. Sit and J. C. Vederas*

J. Am. Chem. Soc. 2017, 139, 17803.

 

13. Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design

Y. Y. Dong, H. Wang, A. C. W. Pike, S. A. Cochrane, S. Hamedzadeh, F. J. Wyszyński, S. R. Bushell, S. F. Royer, D. A. Widdick, A. Sajid, H. I. Boshoff, Y. Park, R. Lucas, W-M. Liu, S. S. Lee, T. Machida, L. Minall, S. Mehmood, K. Belaya, W-W. Liu, A. Chu, L. Shrestha, S. M.M. Mukhopadhyay, C. Strain-Damerell, R. Chalk, N. A. Burgess-Brown, M. J. Bibb, C. E. Barry 3rd, C. V. Robinson, D. Beeson, B. G. Davis* and E. P. Carpenter*.

Cell 2018, 175, 1045.

 

 

 

12. The Antimicrobial Lipopeptide Tridecaptin A₁ Selectively Binds to Gram-Negative Lipid II

S. A. Cochrane, B. Findlay, A. Bakhtiary, J. Z. Acedo, W. M. Rodriguez-Lopez, P. Mercier and J. C. Vederas*

Proc. Natl. Acad. Sci. USA 2016, 113, 11561

Publications figure showing the NMR solution-structure of the tridecaptin A1:lipid II complex 

Recommended in F1000 Prime

 

11. Lipopeptides from Bacillus and Paenibacillus spp.: A Gold Mine of Antibiotic Candidates

S. A. Cochrane and J. C. Vederas*

Med. Res. Rev. 2016, 36, 4

 

10. Synthesis of Tridecaptin-Antibiotic Conjugates with in Vivo Activity Against Gram-Negative Bacteria

S. A. Cochrane, X. Li, S. He, M. Yu, M. Wu and J. C. Vederas*

J. Med. Chem. 2015, 58, 9779

9. Total Synthesis and Stereochemical Assignment of the Antimicrobial Lipopeptide Cerexin A₁

S. A. Cochrane, R. R. Surgenor, K. M. W. Khey and J. C. Vederas*

Org. Lett. 2015, 17, 5428

8. Studies on Tridecaptin B₁, a New Tridecaptin Analogue with Activity Against Multidrug Resistant Gram-Negative Bacteria

S. A. Cochrane, C. T. Lohans, M. J. Van Belkum, M. Bels, and J. C. Vederas*

Org. Biomol. Chem. 2015, 13, 6073

2015 OBC Hot Article

 

7. Molecular Cloning and Characterization of Drimenol Synthase from Valerian (Valeriana officinalis)

M. Kwon, S. A. Cochrane, J. C. Vederas, and D. K. Ro*

FEBS Lett. 2014, 588, 4597

Publications figure showing proposed mechanism of drimenol synthase

 

6. Unacylated Tridecaptin A₁ Acts as an Effective Sensitizer of Gram-Negative Bacteria to Other Antibiotics

S. A. Cochrane and J. C. Vederas*

Int. J. Antimicrob. Agents 2014, 44, 493

 

5. Key Residues in Octyl-tridecaptin A₁ Analogs Linked to Stable Secondary Structure in the Membrane

S. A. Cochrane, B. Findlay, J. C. Vederas and E. S. Ratemi*

ChemBioChem 2014, 15, 1295

 

4. Synthesis and Structure-Activity Relationship Studies of N-Terminal Analogues of the Antimicrobial Peptide Tridecaptin A₁

S. A. Cochrane, C. T. Lohans, J. R. Brandelli, G. Mulvey, G. D. Armstrong and J. C. Vederas*

J. Med. Chem. 2014,  57, 1127

3. Biochemical, Structural and Genetic Characterization of Tridecaptin A₁, an Antagonist of Campylobacter jejuni

C. T. Lohans, M. J. van Belkum, S. A. Cochrane, Z. Huang, C. S. Sit, L. M. McMullen and J. C. Vederas*

ChemBioChem 2014, 15, 243

Publications figure showing putative tridecaptin A1 non-ribosomal peptide synthetase gene cluster

 

2. Investigation of the Ring-Closing Metathesis of Peptides in Water

S. A. Cochrane, Z. Huang and J. C. Vederas*

Org. Biomol. Chem. 2013, 11, 630

OBC Hot Article

 

1. Solid Supported Chemical Synthesis of Both Components of the Lantibiotic Lacticin 3147

W. Liu, A. S. H. Chan, H. Liu, S. A. Cochrane and J. C. Vederas*

J. Am. Chem. Soc. 2011, 133, 14216